ATE269902T1 - Cytokinähnliches polypeptid-10 aus säugetieren - Google Patents

Cytokinähnliches polypeptid-10 aus säugetieren

Info

Publication number
ATE269902T1
ATE269902T1 AT98960493T AT98960493T ATE269902T1 AT E269902 T1 ATE269902 T1 AT E269902T1 AT 98960493 T AT98960493 T AT 98960493T AT 98960493 T AT98960493 T AT 98960493T AT E269902 T1 ATE269902 T1 AT E269902T1
Authority
AT
Austria
Prior art keywords
polypeptide
cytokine
mammal
prevention
antibody
Prior art date
Application number
AT98960493T
Other languages
English (en)
Inventor
Darrell C Conklin
Betty A Haldeman
Angelika Grossmann
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE269902T1 publication Critical patent/ATE269902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
AT98960493T 1997-11-26 1998-11-25 Cytokinähnliches polypeptid-10 aus säugetieren ATE269902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26
PCT/US1998/025228 WO1999027103A1 (en) 1997-11-26 1998-11-25 Mammalian cytokine-like polypeptide-10

Publications (1)

Publication Number Publication Date
ATE269902T1 true ATE269902T1 (de) 2004-07-15

Family

ID=25526742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960493T ATE269902T1 (de) 1997-11-26 1998-11-25 Cytokinähnliches polypeptid-10 aus säugetieren

Country Status (20)

Country Link
EP (3) EP1424393A3 (de)
JP (2) JP5191619B2 (de)
KR (1) KR100574387B1 (de)
CN (2) CN1247780C (de)
AT (1) ATE269902T1 (de)
AU (1) AU739420B2 (de)
BR (1) BR9814904A (de)
CA (1) CA2312000C (de)
CZ (1) CZ300849B6 (de)
DE (1) DE69824755T2 (de)
DK (1) DK1032671T3 (de)
EA (2) EA010741B1 (de)
ES (1) ES2218872T3 (de)
HU (1) HU227703B1 (de)
IL (2) IL136076A0 (de)
NO (2) NO326561B1 (de)
NZ (1) NZ504751A (de)
PL (2) PL198687B1 (de)
UA (2) UA73275C2 (de)
WO (1) WO1999027103A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
JP4741139B2 (ja) 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
WO2001046261A1 (en) * 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
ES2381650T3 (es) 2000-08-08 2012-05-30 Zymogenetics, Inc. Receptores de citoquinas Zcytor11 solubles
JP4908723B2 (ja) 2000-09-15 2012-04-04 ザイモジェネティクス， インコーポレイテッド 炎症を治療するための方法
CA2429044A1 (en) * 2000-10-20 2002-05-02 Zymogenetics, Inc. Secreted alpha-helical cytokine-like protein zlmda24
EP1390060A2 (de) * 2001-01-26 2004-02-25 Eli Lilly And Company Verwendung von lp82 zur behandlung von störungen des körpergewichtes
WO2002070001A2 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
US20040204351A1 (en) * 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
CA2467723C (en) 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
EP1606316A2 (de) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antikörper und bindungspartner und verwendungsmethode bei entzündung
WO2005014028A1 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
DE602004023965D1 (de) * 2003-11-21 2009-12-17 Zymogenetics Inc Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
JP4870574B2 (ja) 2003-12-19 2012-02-08 ノヴォ ノルディスク アー／エス ペプチドおよびタンパク質のプロセシング
EP2033662B1 (de) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase vermittelte konjugation von peptiden.
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
JP4898691B2 (ja) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
EP2192132A3 (de) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
EP2636756B2 (de) 2008-05-27 2019-11-20 Dako Denmark A/S Zusammensetzungen und Verfahren zur Erkennung von chromosomalen Abweichungen mit neuen Hybridisierungspuffern
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
WO2010042634A1 (en) * 2008-10-07 2010-04-15 National Cheng Kung University Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
EP2401396B1 (de) 2009-02-26 2016-11-23 Dako Denmark A/S Verfahren zur durchführung eines stringenten waschschritts bei hybridisierungsanwendungen
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (de) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
JP5976849B2 (ja) * 2012-03-05 2016-08-24 シージーン アイエヌシー ＰＴＯ切断及び伸長アッセイによるターゲット核酸配列でのヌクレオチド変異検出｛ＤｅｔｅｃｔｉｏｎｏｆＮｕｃｌｅｏｔｉｄｅＶａｒｉａｔｉｏｎｏｎＴａｒｇｅｔＮｕｃｌｅｉｃＡｃｉｄＳｅｑｕｅｎｃｅｂｙＰＴＯＣｌｅａｖａｇｅａｎｄＥｘｔｅｎｓｉｏｎＡｓｓａｙ｝
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
WO2018200620A1 (en) 2017-04-25 2018-11-01 National Cheng Kung University Use of il-20 antagonists for treating eye diseases
BR112022006862A2 (pt) * 2019-10-10 2022-07-05 Univ New York State Res Found Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424410T1 (de) * 1996-08-30 2009-03-15 Human Genome Sciences Inc Interleukin-19.
WO2001046261A1 (en) * 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation

Also Published As

Publication number Publication date
HU227703B1 (en) 2011-12-28
DE69824755T2 (de) 2005-08-04
EP1424393A3 (de) 2004-06-09
DK1032671T3 (da) 2004-10-11
IL136076A0 (en) 2001-05-20
EA010741B1 (ru) 2008-10-30
BR9814904A (pt) 2000-10-03
AU1607799A (en) 1999-06-15
EP1032671B1 (de) 2004-06-23
EA200000565A1 (ru) 2000-12-25
EP1719780A2 (de) 2006-11-08
EA005581B1 (ru) 2005-04-28
CA2312000A1 (en) 1999-06-03
IL136076A (en) 2007-12-03
JP5191619B2 (ja) 2013-05-08
EP1032671A1 (de) 2000-09-06
PL198687B1 (pl) 2008-07-31
DE69824755D1 (de) 2004-07-29
WO1999027103A1 (en) 1999-06-03
KR20010032490A (ko) 2001-04-25
CZ20001910A3 (cs) 2000-11-15
NZ504751A (en) 2001-10-26
KR100574387B1 (ko) 2006-04-27
NO20002698L (no) 2000-07-20
NO20002698D0 (no) 2000-05-26
NO329731B1 (no) 2010-12-13
CA2312000C (en) 2013-03-26
JP5331054B2 (ja) 2013-10-30
AU739420B2 (en) 2001-10-11
ES2218872T3 (es) 2004-11-16
UA86350C2 (en) 2009-04-27
EA200401501A1 (ru) 2006-02-24
HUP0100436A2 (hu) 2001-06-28
NO20074516L (no) 2000-07-20
HUP0100436A3 (en) 2003-08-28
CN1282372A (zh) 2001-01-31
EP1424393A2 (de) 2004-06-02
JP2001524313A (ja) 2001-12-04
PL195304B1 (pl) 2007-08-31
PL340755A1 (en) 2001-02-26
CN1247780C (zh) 2006-03-29
UA73275C2 (en) 2005-07-15
CN1618969A (zh) 2005-05-25
NO326561B1 (no) 2009-01-12
EP1719780A3 (de) 2006-12-20
CZ300849B6 (cs) 2009-08-26
JP2010187698A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
ATE269902T1 (de) Cytokinähnliches polypeptid-10 aus säugetieren
PT839196E (pt) Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
SE8901687D0 (sv) Fibronectin binding protein as well as its preparation
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
ATE378408T1 (de) Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
ATE403726T1 (de) Cytokin-proteinfamilie
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
DE69739071D1 (de) Menschliche tak1 und für diese kodierende dna
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
KR950704352A (ko) 테라포시데 아포노펠마로부터의 칼슘 통로 차단 폴리펩티드(calcium channel blocking polypeptides from theraphosidae aphonopelma)
NZ606260A (en) Novel polypeptides involved in immune response
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032671

Country of ref document: EP